Emerging role of sertindole in the management of schizophrenia

• Published in: Neuropsychiatric disease and treatment Vol. 6; no. 1; pp. 429 - 441
• Main Authors: Cincotta, Stephanie L, Rodefer, Joshua S
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 07-09-2010; Dove Press; Dove Medical Press
• Subjects: 5-HT2; 5-HT6; antipsychotic; Antipsychotics; atypical; cognition; Expert Opinion; psychosis; Psychotropic drugs; Schizophrenia; 5-HT6; antipsychotic; cognition; atypical; 5-HT2; psychosis
• ISSN: 1176-6328; 1178-2021; 1176-6328
• DOI: 10.2147/NDT.S7602

The atypical antipsychotic sertindole is a phenylindole-derived compound that has affinity for and functions as an antagonist at a number of receptor systems, including dopamine D2 receptors, 5-HT(2A) and 5-HT(2C) receptors, and α-1-noradrenergic receptors. Although previous data suggested that sertindole was well tolerated and had good efficacy against both positive and negative symptom clusters, reports of QT prolongation with sertindole prompted its voluntary removal from the market in 1998. After further safety analyses, it recently regained approval and was reintroduced to the European market for the treatment of schizophrenia, where its role in therapy among available atypicals remains unclear. This article evaluates the preclinical and clinical data regarding sertindole's effectiveness and concludes that sertindole continues to demonstrate a number of strengths, including effective management of both positive and negative symptoms, well-tolerated side effects (including little or no sedation, weight gain, and extrapyramidal side effects), and a superior procognitive profile that is unique among atypical antipsychotics. However, minor concerns regarding its sexual side effects and the major consideration of QT prolongation suggest that additional comparative effectiveness studies are needed to determine the superiority of sertindole vs other atypical antipsychotics recently introduced.